GlassScriptPhysician profile
Megan E Daniels
NPI 1053827469
$5,724.22
in general payments reported to CMS, 2019-2025
24 companies · $2,778 in 2025
The $2,778 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.08 · 2022: $207 · 2023: $584 · 2024: $2,073 · 2025: $2,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,435.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,130.55 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $856.62 | 2023-2025 | |
| Janssen Biotech, INC. | $835.73 | 2022-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $359.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $344.68 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $264.63 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $263.11 | 2024-2025 | Vowst |
| Genzyme Corporation | $226.36 | 2023-2025 | |
| Gilead Sciences, INC. | $182.41 | 2025 | Livdelzi |
| Lilly USA, LLC | $153.47 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $153.07 | 2022 | |
| Ardelyx, INC. | $150.96 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $135.29 | 2023-2025 | Linzess |
| Pharmacosmos Therapeutics INC. | $104.07 | 2025 | Monoferric |
| Merck Sharp & Dohme LLC | $91.47 | 2023-2024 | Dificid, Zerbaxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $90.80 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $88.92 | 2024 | Voquezna |
| Medtronic, INC. | $71.10 | 2023 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.41 | 2022-2025 | Xifaxan |
| Braintree Laboratories, INC. | $53.19 | 2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $31.66 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.86 | 2023 | Cyltezo |
| Dynavax Technologies Corporation | $29.65 | 2024 | Heplisav-B |
| Echosens North America, INC. | $9.93 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.